Key result
Vitamin D3 supplementation at 4000 IU daily for 6 months did not improve endothelial function compared to placebo in patients with chronic heart failure, although it did improve walking distance and left atrial diameter.
Why the study?
Low 25-hydroxyvitamin D levels are common in chronic heart failure and linked to increased mortality, but the safety, efficacy, and effects of oral vitamin D3 supplementation on endothelial and ventricular function remained unclear.
Does vitamin D3 supplementation improve endothelial function in patients with stable chronic heart failure and vitamin D deficiency?
RCT (n=73)
Double-blind
1:1 ratio
Yes
Does vitamin D3 supplementation improve endothelial function in patients with stable chronic heart failure and vitamin D deficiency?
High-dose vitamin D supplementation in stable heart failure patients with vitamin D deficiency does not improve endothelial function or left ventricular remodeling, but may improve symptoms, exercise capacity, and left atrial diameter.
Answers are grounded in this paper and cite their sources.
4000 IU daily vitamin D3 appears safe in stable HF; extends evidence for ventricular but not endothelial effects.
BACKGROUND: Low 25-hydroxyvitamin D (25OHD) levels are common in patients with chronic heart failure (HF) and are associated with increased mortality risk. This study aimed to establish the safety and efficacy of oral vitamin D3 (cholecalciferol) supplementation and its effect on endothelial and ventricular function in patients with stable HF. METHODS: This study was an investigator-initiated, multicenter, prospective, randomized, placebo-controlled trial. Seventy-three HF patients with 25OHD levels < 75 nmol/L (30 ng/mL) were randomized to receive 4000 IU vitamin D daily or a placebo for 6 months. The primary endpoint was a change in endothelial function between the baseline and after 6 months as assessed using EndoPAT. Secondary endpoints included changes in echocardiographic parameters and differences in quality of life (6-min walking test and New York Heart Association functional status) at 6 months. RESULTS: There were no adverse events in either group during the study period. Vitamin D supplementation did not improve endothelial dysfunction (EndoPAT: baseline, 1.19 ± 0.4 vs 6 months later, 1.22 ± 0.3, P = .65). However, patients' blood pressure, 6-min walking distance, and EQ-5D questionnaire scores improved after vitamin D treatment. In addition, a significant reduction in the left atrial diameter was observed. CONCLUSION: A daily vitamin D dose of 4000 IU for chronic HF appears to be safe. This dosage did not improve endothelial function but did improve the 6-min walk distance, symptoms, and left atrial diameter at 6 months.
No takes yet. Share an insight, caveat, or question.
Woo et al. (2022) conducted an RCT in chronic heart failure (n=73). Vitamin D3 (cholecalciferol) vs. Placebo was evaluated on Difference in endothelial function assessed by pulse amplitude tonometry (EndoPAT) from baseline to 6 months (p=0.47). Vitamin D3 supplementation at 4000 IU daily for 6 months did not improve endothelial function compared to placebo in patients with chronic heart failure, although it did improve walking distance and left atrial diameter.
Synapse has enriched 10 related papers. Consider them for comparative context: